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Introduction
Th   e idiopathic inﬂ  ammatory myopathies (IIMs) repre  sent 
a group of rare and heterogeneous ‘orphan’ auto  immune 
diseases characterized by inﬂ  ammation of skele  tal muscle 
and other organ systems, potentially leading to irrever-
sible damage and resulting disability. Th  e etio  patho-
genesis of IIM is likely to result from an interaction of 
genetic and environmental factors, which together are 
required to initiate the onset of a clinical disease pheno-
type [1]. IIMs traditionally have been classiﬁ  ed broadly 
according to a limited set of subtypes: polymyositis (PM), 
dermatomyositis (DM), myositis overlapping with another 
connective tissue disease (myositis-CTD/overlap), inclu-
sion body myositis (IBM), and juvenile dermatomyositis 
(JDM). However, serological status according to circulat-
ing myositis-speciﬁ   c antibodies (MSAs) or myositis-
associated antibodies (MAAs) is proving to be increas-
ingly useful in the classiﬁ  cation of IIM and often corre-
lates with deﬁ  ned IIM clinical phenotypes.
To date, our understanding of IIM immunogenetics has 
increasingly been facilitated by candidate gene studies 
examining the frequency of selected polymorphisms in 
IIM cases compared with controls. Historically, these 
studies have often included considerably heterogeneous 
IIM populations in order to increase statistical power. To 
facilitate meaningful research in rare diseases such as 
IIM, present and future approaches must include careful 
recruitment of conﬁ   rmed ethnically homogeneous 
cohorts, and this requires collaboration across national 
and international recruitment centers. Already, new 
tech  nologies mean that genome-wide association scans 
are now the norm in the genetic investigation of complex 
genetic diseases. Th   e remit of this article is to discuss and 
summarize what is currently known about the immuno-
genetics of IIM and to concentrate on candidate gene 
studies that currently provide the best evidence for a 
genetic basis in IIM.
    The evidence for a genetic basis in myositis
Th   ere is increasing evidence to suggest a genetic basis in 
IIM, but owing to the scarcity of aﬀ  ected sibling pairs and 
twins, this evidence currently comes from anecdotal 
familial aggregation and candidate gene studies only 
[2,3]. To date, no IIM familial linkage or twin studies have 
been published, and the ‘heritability’ of the disease (λs) is 
unknown. Th   e scarcity of familial IIM cases suggests that, 
when encountering two or more ﬁ  rst-degree  family 
members with symptoms and signs in keeping with 
possible IIM, attending physicians should be highly 
suspicious of making such diagnoses without careful 
clinicopathological correlation. If necessary, DNA or 
further biochemical analysis or both should also be con-
ducted at a specialized neuromuscular center to exclude 
non-inﬂ  ammatory forms of neuromuscular disease such 
as dystrophies, mitochondrial, or metabolic myopathies.
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Th   e evidence for familial aggregation in IIM arises from 
case reports, the ﬁ  rst of which was by Wedgwood and 
colleagues [4], who described JDM in twins, whose onset 
occurred within a year of each other. Other cases, in 
which two or more family members suﬀ   er from IIM 
(including DM, PM, IBM, and orbital and amyopathic 
myositis), have since been described [2].
Rider and colleagues [5] recruited 36 patients with PM, 
DM, or IBM from 16 unrelated families in which two or 
more individuals fulﬁ  lled criteria for probable or deﬁ  nite 
myositis. A cohort of non-familial IIM cases (n = 181) 
was used as a comparison group. MSAs were more 
frequent in the non-familial compared with the familial 
myositis group. HLA-DRB1*0301 was a signiﬁ  cant risk 
factor in both familial and non-familial disease versus 
controls, but the genetic contribution in familial cases 
was less than that of non-familial cases (attributable risk 
of 0.35 versus 0.51). Homozygosity in a combined 
analysis of all studied HLA-DQA1 alleles combined 
proved a risk factor for familial disease. Th  e modest 
diﬀ   erences between familial/non-familial IIM cases 
suggest that there may be further as-yet-unidentiﬁ  ed 
environmental and genetic factors in IIM [5].
HLA candidate gene studies
To date, the strongest immunogenetic associations found 
in IIM arise from the MHC region in a fashion analogous 
to that of other autoimmune diseases [6]. Given the rarity 
of IIM, early candidate gene studies examined only small 
numbers of patients and often grouped clinical IIM sub-
groups together (including PM, DM, IBM, and JDM) in 
an eﬀ   ort to increase statistical power. In some early 
studies, even patients of diﬀ   ering ethnic groups were 
exam  ined together. Studies in the last 5 years have 
attemp  ted to address these case-selection issues by strati-
fy  ing cases according to ethnic, clinical, and serological 
subtypes.
Alleles forming part of the 8.1 Caucasian MHC 
common ancestral haplotype (HLA-A1-B8-Cw7-
DRB1*0301-  DQA1*0501-C4A*Q0) occur in strong link-
age disequilibrium within Caucasian populations in 
Northern and Western Europe, and this haplotype 
represents a risk factor for a large number of immuno-
pathological diseases [7]. To date, the 8.1 haplotype has 
also been identiﬁ  ed as a major risk factor in IIM (Table 1) 
[5,8-22].
Th  e HLA associations observed in IIM subgroups of 
Caucasian ethnicity are not generally found in other non-
Caucasoid populations, although alleles of the 8.1 
haplotype have been described in two studies of African-
American IIM [11,18]. No HLA associations have been 
found in Mexican-American or Korean myositis popu-
lations, illustrating the importance of stratiﬁ  cation  by 
ethnicity in such studies [10,12].
Recent larger studies have enabled the identiﬁ  cation 
and characterization of HLA alleles that act as risk as well 
as protective factors in diﬀ   erent IIM phenotypes. For 
example, HLA-DRB1*0301 represents a strong PM risk 
factor whereas HLA-DQA1*0201 confers protection in 
the same clinical phenotype [12,13]. Th   e concept of shared 
alleles within deﬁ  ned haplotypes may also contribute to 
this. For example, in PM, the high frequency of the 8.1 
haplotype may be responsible, in part, for lowering the 
frequency of DRB1*07-DQA1*02-DQB1*02 and this is 
due to the shared DQB1*02 allele within both haplotypes. 
Th   is combination of risk and protection may contribute 
to the stability and exclusivity of IIM phenotypes [23]. A 
primary amino acid sequence of HLA-DRB1 alleles 
known to share a peptide-binding motif has been 
described in IIM. Th  is sequence is called 9EYSTS13 and 
refers to the ﬁ   rst hypervariable HLA-DRB1 region 
sequence, which is shared by the DRB1*03, 11, 13, and 1  4 
alleles (Table 1). A strong asso  ciation has been found for 
anti-Mi-2 positivity in a poly  morphism that also incor-
por  ates the ﬁ  rst hypervariable region but that codes for 
an aromatic tryptophan residue at position 9 (HLA-
DRB*01, 02, 07) [24]. Further HLA peptide-binding 
motifs and haplotypes that are both risk and protective 
factors in IIM have been described in larger-scale studies. 
Th  ese  ﬁ   ndings emphasize the importance of HLA 
haplotypes and peptide-binding motifs in discriminating 
between IIM clinical and serological subtypes [12,13,25].
H       LA  associations  with  myositis  autoantibodies
HLA alleles are known to be strongly associated with the 
likelihood of developing MSAs/MAAs in IIM, in which 
the strength of association is considerably greater than 
that in association with stratiﬁ  cation by traditional clinical 
subtype (Table 2) [9,11,13,16,18,24-28]. Th   is suggests that 
stratiﬁ   cation by serological, rather than traditional 
clinical, subtype represents a more homogeneous form of 
IIM classiﬁ  cation [13,29].
Th   e association of anti-Jo-1 antibodies and alleles com-
prising the 8.1 haplotype has been conﬁ  rmed in several 
studies [11,13,29-31]. Th  is strong relationship between 
HLA and serological subtype is also present for other 
MSAs/MAAs, in which antibodies other than anti-Jo-1 
are associated with other haplotypes. However, HLA 
alleles comprising the 8.1 haplotype are also strongly 
associated with the presence of anti-PM-Scl antibodies, 
an MAA often associated with myositis/sclerodema 
overlap syndrome [28]. Th   is antibody/phenotype associa-
tion has been conﬁ  rmed in a UK JDM population [15]. 
Mierau and colleagues [24] demonstrated that HLA-
DRB1*0701 represented a strong risk factor in German 
Caucasian anti-Mi-2 antibody-positive patients versus 
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larger studies [13,25,26]. HLA-DQA1*0201, known to 
share strong linkage disequilibrium with DRB1*0701, 
also confers risk in anti-Mi-2 antibody-positive cases. 
Th   e strong relationship between HLA and these MSAs/
MAAs may partly explain the exclusivity that these 
antibodies possess, as illustrated by the extreme rarity of 
multiple MSAs in the same patient. It is currently unclear 
whether strong associations exist with HLA alleles 
among rarer MSAs, although a recent US study has 
identiﬁ  ed potential genetic risk factors for SRP and the 
less frequent anti-synthetases [25].
Th  ese HLA-related risk factors among serological 
subgroups clearly diﬀ  er according to ethnicity (Tables 1 
and 2HLA associations in ethnically diﬀ  erent myositis 
populations). For example, African-Americans with IIM 
do not share the 8.1 haplotype-related risk in the same 
way as Caucasians. However, a recent large-scale US 
study showed that African-Americans with either DM or 
anti-Jo-1 antibodies do appear to share the risk of HLA-
DRB1*0301 with Caucasians [18]. Furthermore, HLA-
DRB1*0302 is a signiﬁ   cant risk factor for anti-Mi-2 
antibody-positive African-American cases. Th  is latter 
allele shares amino acid side chains coded for by the 
Caucasian anti-Mi-2 risk factor DRB1*0701, and further 
comparative analyses suggested identical orientations 
within the peptide-binding groove. In a recent smaller 
study of UK-based non-Caucasians, HLA-DRB1*03 was 
also detected as a risk factor in anti-Mi-2 and anti-PM-
Scl antibody-positive cases [32]. Th   e issue of shared HLA 
susceptibility risk factors across ethnic groups may 
suggest aﬃ   nity for common antigenic peptides. However, 
the results of these non-Caucasoid studies also highlight 
that the between-ethnic diﬀ   erences demonstrated for 
myositis genotype, serotype, and phenotype need to be 
taken into account when making future case-case or 
case-control comparisons.
Tumor necrosis factor-alpha
TNF-α is a proinﬂ   ammatory cytokine with a diverse 
range of activities, playing a major role in immune res-
ponse regulation. Th  e  TNF-α gene is encoded within the 
MHC class III region, and associated SNPs have been 
impli  cated in many autoimmune diseases, including 
dermatitis herpetiformis, systemic lupus erythematosus, 
ankylosing spondylitis, and Crohn’s disease, and also in 
various infectious diseases, including malaria, leprosy, 
and hepatitis B/C [7].
A TNF-α promoter SNP at position -308 (rs1800629), 
resulting from a G-to-A substitution has been associated 
with IIM in a number of candidate gene studies [33-36]. 
In a recent juvenile DM study, homozygosity for the A 
allele of the TNFα-308 SNP was shown to confer risk for 
soft-tissue calcinosis (9% calci  nosis versus 1% no calci-
nosis, corrected P value (Pcorr) = 0.045, odds ratio (OR) 
7.3, 95% conﬁ   dence interval (CI) 1.4 to 37.2) [36], 
Table 1. HLA a  ssociations   in ethnically diff  erent myositis populations
Population Ethnicity  Allele  Reference
IIM  Caucasian  HLA common ancestral Haplotype (A1;B8;DR3)  [5,8-15]
IIM  Caucasian  EYSTS, DRB1 HVR motif  [10,12,14]
PM Caucasian  Cw*0701
   DRB1*0401  (protective)  [12]
   DQA1*0201  (protective)
PM Caucasian  DRB1*07  (protective)  [13]
   DQA1*02  (protective)
PM Caucasian  DPB1*0101  [16]
DM Caucasian  A*68  [12]
   DQA1*01  (protective)
Familial IIM  Caucasian  DQA1 homozygosity  [5]
JDM Caucasian  DMA*0103  [17]
IIM African-American DRB1*14  (protective)  [18]
IIM African-American B7;  DRw6  [19]
DM/JDM African-American  DRB1*0301  [18]
JDM African-American  DQA1*0501  [20]
JDM Hispanic  DQA1*0501  [20]
JDM Hispanic  DR3  [21]
PM Japanese  DRB1*0803  [22]
All listed risk/protective factors are risk alleles/haplotypes unless stated otherwise. Data are presented only if results remain signifi  cant after corrections for multiple 
comparisons are applied to probability values. DM, dermatomyositis; IIM, idiopathic infl  ammatory myopathy; JDM, juvenile dermatomyositis; PM, polymyositis.
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Antibody Ethnicity  Allele  P value  OR, 95% CI  Reference
Anti-Jo-1 Caucasian  DRB1*0301  P = 0.00004  9.6, 2.9-36.3  [11]
     Pcorr <0.0001  15.5, 8.3-30.2  [25]
   DQB1*0201  P = 0.0002  8.3, 2.2-46.1  [11]
   B*08  Pcorr <0.0001  21.7, 9.4-55.4  [25]
   C*0701  Pcorr <0.0001  15.7, 6.4-41.5 
   DRB1*01 Pcorr = 0.008  0.3, 0.1-0.6 
   DQA1*0201 Pcorr <0.0001  0.1, 0.1-0.4 
   DQA1*0501  Pcorr <0.0001  5.1, 2.7-10.4 
   DPB1*0101  Pcorr <0.00003  4.1, 2.1-7.8  [16]
Anti-Jo-1 African-American  B*08  P = 0.02  7.6, 2.1-27.4  [18]
   DRB1*0301  P = 0.001  6.7, 2.5-18.0 
Anti-PL-7 Caucasian  C*0304  Pcorr = 0.05  25.3, 2.2-1,257.8  [25]
Anti-PL-12 Caucasian  DRB1*0301  Pcorr = 0.01  13.5, 2.6-131.2  [25]
Anti-synthetase Caucasian  DRB1*03  Pcorr = 1 × 10−14 14.1,  6.3-35.2  [13]
   DRB1*0301  Pcorr <0.008  40.1, 4.2-1,861  [9]
   DQA1*05  Pcorr = 4 × 10−8 9.5,  3.8-36.5  [13]
   DQA1*0501  Pcorr <0.008  16.7, 1.9-770.2  [9]
   DQB1*02  Pcorr = 4 × 10−8  9.5, 3.8-36.5  [13]
Anti-Mi-2 Caucasian  DRB1*07  Pcorr = 0.00005  11.1, 3.4-46.8  [13]
   DRB1*0701  P <0.0001  22, 4.6-105  [24]
     P <0.001  18.7, 2.1-873.4  [26]
     Pcorr = 0.002  4.9, 2.2-11.5  [25]
   DQA1*02  Pcorr = 0.00005  11.6, 3.3-50.6  [13]
   DQA1*0201  P <0.0001  20.2, 4.4-93  [24]
     P <0.001  19.8, 2.2-923.3  [26]
     Pcorr = 0.002  3.3, 1.5-7.5  [25]
   DQB1*02  Pcorr = 0.004  7.5, 2.0-41.9  [13]
Anti-Mi-2 Hispanic  DRB1*04  Pcorr <0.01  4.7, 1.7-13.3  [26]
   DQA1*03  Pcorr <0.001  7.0, 2.3-22.8 
Anti-Mi-2 African-American  DRB1*0302  P = 0.0005  23.6, 4.2-234.2  [25]
   DQA1*0401  P = 0.0008  25.2, 3.2-1,106 
Anti-SRP Caucasian  B*5001  Pcorr = 0.02    [25]
Anti-SRP African-American DQA1*0101  P = 0.04  3.6, 1.4-9.8  [18]
Anti-PM-Scl Caucasian  DRB1*03  P <0.0001    [27]
     P <0.0001  10.6, 3.4-38.7  [28]
     Pcorr = 0.00004  30.6, 4.4-1,309.1  [13]
   DRB1*0301  Pcorr <0.008  100, 13.1-4,258  [9]
     Pcorr <0.0001  77.5, 19.6-663.8  [25]
   DQA1*0101  Pcorr = 0.003  0.2, 0.05-0.5  [25]
   DQA1*05  Pcorr = 0.001  18.9, 2.6-814.9  [13]
   DQA1*0501  Pcorr <0.008  16.5, 1.9-763.4  [9]
     Pcorr <0.0001  15.2, 4.8-77.1  [25]
   DQB1*02  Pcorr = 0.001  18.0, 2.5-777.4  [13]
Anti-Ku Caucasian  DRB1*0301  Pcorr <0.008  38.1, 4.1-1,768  [9]
   DQA1*0501  Pcorr <0.008  16.5, 1.9-763.4 
   DRB1*11  Pcorr <0.04  21.3, 2.1-1,049.8  [25]
P values are uncorrected (unless otherwise stated), and associations given are odds ratios (ORs) and 95% confi  dence intervals (CIs) versus controls. Alleles in italics 
refer to protective factors. Pcorr, corrected P value.
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However, in both adult and juvenile IIM, other alleles 
forming part of the 8.1 haplotype have been reported to 
confer the primary association over and above that 
resulting from TNFα-308A [36,37].
It is known that subjects with the 8.1 haplotype have an 
altered immune response and thus immune stress may 
produce an imbalanced array of cytokines [38]. In a study 
of normal subjects, stratiﬁ  ed by the presence or absence 
of the 8.1 haplotype, TNF-α levels in both serum and 
stimulated mononuclear cells were signiﬁ  cantly higher in 
8.1 haplotype-positive versus -negative carriers (P <0.0005) 
[39]. Studies have suggested a genetic contribution to 
TNF-α regulation, in which TNFα-308A and other TNF-α 
gene polymorphisms are associated with higher-circulat-
ing levels of TNF-α [40]. Th  ese ﬁ  ndings have also been 
suggested from IIM studies [33]. B-cell activating factor 
(BAFF) and a proliferation-inducing ligand (APRIL) are 
members of the TNF superfamily and have key functions 
in both B- and T-cell homeostasis, and both ligands are 
signiﬁ  cantly increased in the serum of IIM cases versus 
controls [41]. Th  e TNFα-308A polymorphism therefore 
may have functional signiﬁ   cance in driving an altered 
immune response. Supporting evidence for this comes 
from a gene expression study in juvenile DM, the results 
of which suggested that TNF-α was a key molecule 
within a pathogenesis model that included antiviral, 
ischemic, and degeneration/regeneration processes [42]. 
However, identiﬁ  cation of the relevant functional variant 
at the TNF-α locus is complicated by the presence of 
extensive linkage disequilibrium within this region.
HLA-DPB1 associations
Genetic variations outside of the traditional 8.1 haplotype 
region may be involved in determining serotype/pheno-
type diﬀ  erences. Th   e HLA-DPB1 gene lies at the centro-
meric end of MHC and is separated from other HLA 
class II loci by one or more genetic recombination 
hotspots, which may weaken the degree of any linkage 
disequilibrium with other class II loci [43].
In a UK-based cohort of 311 adult- and juvenile-onset 
PM, DM, or myositis/CTD-overlap cases, a strong asso-
ciation was observed between HLA-DPB1*0101 and the 
presence of anti-Jo-1 antibodies (Table 1) [44]. Despite 
the strong association of HLA-DRB1*03 with both anti-
Jo-1 and anti-PM-Scl antibodies, no signiﬁ  cant diﬀ  erence 
was noted in the frequency of HLA-DPB1*0101 between 
anti-PM-Scl antibody-positive cases (15%) and controls 
(13%). Furthermore, a signiﬁ  cant  diﬀ   erence at HLA-
DPB1*0101 was noted when anti-Jo-1- and PM-Scl-
positive cases were compared with each other, and this 
allele was much more common in anti-Jo-1 cases (37% 
Jo-1 versus 15% PM-Scl, uncorrected P = 0.03, OR 3.3, 
95% CI 1.01 to 12.7). Th   us, additional disease 
susceptibility signals for anti-Jo-1 may be present in the 
centromeric end of the MHC region. Th  ese additional 
signals genetically discriminate risk for anti-Jo-1 from 
that of anti-PM-Scl antibodies. Fine mapping and further 
detailed HLA analyses in large-scale colla  borations are 
now required within the MHC to carefully investigate 
these diﬀ  erences.
Progress outside of major histocompatibility 
complex
Mannose-binding lectin 2 polymorphisms
Mannose-binding lectin (MBL2) is a protein that may 
play a role in reducing photosensitive autoimmunity by 
altering the clearance of apoptotic cells [45]. Several 
polymorphisms have been described in the MBL gene 
and can aﬀ  ect serum MBL concen  trations. One such SNP 
(GlyAsp, codon 42, exon 1, rs1800450), known to be 
associated with low serum MBL concentrations, was 
studied in a small US study com  par  ing DM cases with 
cutaneous lupus erythematosus cases and controls [45]. 
Th  is MBL polymorphism was signiﬁ    cantly increased in 
DM (P = 0.0004) but not cutaneous lupus erythematosus 
versus controls. Combinations of low-producing MBL 
variants were also associated with DM, but again not in 
subacute cutaneous lupus erythematosus. It was thus 
hypothesized that these MBL polymorphisms could 
inﬂ  uence the pathogenesis of DM by inﬂ  uencing over-
production of apoptotic keratinocytes and impairing the 
clearance of such apoptotic cells.
Immunoglobulin gene polymorphisms
Immunoglobulin gene polymorphisms encoding constant 
regions of immunoglobulin gamma heavy (GM, 14q32.33) 
and kappa light (KM, 2p12) chains have been examined 
in a series of US Caucasian and African-American IIM 
cohorts [10,26,46]. A number of studies have examined 
individuals with allelic variants of speciﬁ  c  GM/KM 
genes, in which raised titres of speciﬁ   c IgG antibody 
subclasses were present, against various antigenic 
epitopes of infectious disease agents or self-proteins [46]. 
Th  e most recent study of GM/KM allotypes, in 514 US 
Caucasian and 123 African-American adult/juvenile IIM 
cases [46], adds to previous studies of Mesoamerican and 
Korean populations [10,26]. Th   e GM 13 allotype showed 
the strongest association in Caucasian juvenile DM 
versus controls (Pcorr <0.0001, OR 3.9, 95% CI 2.26 to 
6.76). When analyzed as a paired combination with either 
the KM 1 or 3 allotype, the GM marker also conferred 
risk in Caucasian adult IIM (Pcorr <0.004 for each pair). In 
adults, the GM 3 23 5,13 phenotype was signiﬁ  cantly 
increased in anti-Jo-1 antibody-positive adult DM cases 
versus controls (Pcorr = 0.0031, OR 3.4, 95% CI 1.68 to 
7.12). Other GM/KM markers also diﬀ  erentiated 
between the Caucasian and African-American cohorts. 
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two indepen  dent loci outside of the HLA system. It 
would be interesting to examine these markers in 
geographically diverse populations to conﬁ  rm  the 
ﬁ   ndings and to further test the apparent ethnic 
heterogeneity with these loci.
Protein tyrosine phosphatase N22
Previous large-scale genetic association studies have 
conﬁ  rmed a missense SNP in the protein tyrosine phos-
phatase N22 (PTPN22) gene in association with a variety 
of autoimmune diseases [47]. At position 1858 of the 
PTPN22 gene, a CT change (rs2476601) leads to an 
amino acid substitution (argininetryptophan, R620W) 
in the lymphocyte phosphatase (LYP) protein, thought to 
be a ‘gain-of-function mutation’. Th   e LYP*W620 is able to 
dephosphorylate signaling proteins more eﬃ   ciently than 
LYP*R620, leading to increased T- and B-lymphocyte 
inhibition, thymic hypo-responsiveness, and an increase 
in circulating autoreactive T cells [48]. Th  e  PTPN22 gene 
has been investigated in a large, adult and juvenile UK 
IIM cohort [49]. Th  e results showed that the R620W 
polymorphism was associated with the combined adult/
juvenile IIM group (13.6% IIM versus 8.2% controls, 
Pcorr <0.0009, OR 1.8, 95% CI 1.3 to 2.4) and also within 
the adult PM (16.4% PM, Pcorr = 0.003, OR 2.2, 95% CI 1.4 
to 3.3) and juvenile DM (15.9% juvenile DM, Pcorr = 0.009, 
OR 2.1, 95% CI 1.3 to 3.3) subgroups. Importantly, this 
IIM/PTPN22 association was shown to be independent 
of the 8.1 haplotype. Other PTPN22 SNPs were exam-
ined, but only a haplotype incorporating the minor T 
allele of R620W conferred any signiﬁ   cant degree of 
suscep  tibility for IIM. Unlike the described HLA asso-
ciations with IIM, no associations were observed within 
serological subgroups after corrections for multiple com-
parisons. Th  us, the R620W variant appears to be a risk 
factor for IIM regardless of MSA/MAA status, implying a 
risk for general autoimmunity rather than conferring risk 
for a speciﬁ  c serological subtype (cf HLA) Th  e  eﬀ  ect size 
of this SNP in conferring risk for IIM is in keeping with 
observations for other autoimmune diseases such as 
rheumatoid arthritis.
Interleukin 1
Proinﬂ   ammatory cytokines such as TNF-α and inter-
leukin 1 (IL1) α/β are overexpressed in inﬂ  ammatory cell 
inﬁ  ltrates and on the surface of skeletal muscle cells in 
IIM muscle biopsy samples. IL1α/β are also over  ex-
pressed in capillary endothelium in aﬀ  ected IIM muscle. 
A recent study examined IL1 cytokine poly  morphisms in 
juvenile DM [36]. Th  e  IL1B+3953T allele polymorphism 
(rs1143634) conferred risk (53% IIM versus 40% controls, 
Pcorr = 0.038, OR 1.7, 95% CI 1.1 to 2.6) and the 
IL1A+4845G polymorphism (rs17561) was protective for 
juvenile DM (77% IIM versus 88% controls, Pcorr = 0.011, 
OR 0.46, 95% CI 0.27 to 0.79). Other possible cytokine 
gene associations with IIM (interferon gamma, chemo-
kine (C-C motif) receptor 2) have been investigated in 
UK adult IIM studies, but no robust associations were 
found [50,51].
Inclusion body myositis
Th  e recent larger-scale IIM candidate gene studies 
already cited have not concentrated on IBM, and, conse-
quently, little progress has been made in the study of IBM 
immunogenetics. Previous IBM genetic studies have con-
tained only small numbers of patients and have concen-
trated on the HLA region [3,52]. Consequently, global 
collaborative eﬀ   orts between neurology and rheuma-
tology are now required to readdress this recruitment 
issue.
A recent study investigated HLA class I and II asso-
ciations in a cohort of 80 Australian sporadic IBM cases 
compared with 190 controls [53]. Th  e association with 
HLA-DR3 and IBM was conﬁ  rmed (75% IBM versus 23% 
controls, P <0.01, OR 9.56, 95% CI 5.12 to 18.96). In a 
case-control subanalysis of DR3-positive carriers, the 
frequency of HLA-DR3/DR1 heterozygotes was signiﬁ  -
cantly increased in IBM compared with controls 
(P <0.003). Within this subgroup, the mean age of onset 
of disease was signiﬁ  cantly lower when compared with 
the remaining patients (55.8 years versus 62.3 years, P = 
0.006). Th  e average quadriceps femoris muscle strength 
was lower in HLA-DR3-positive compared with HLA-
DR3-negative cases after disease duration and treatment 
were adjusted for (P = 0.01), conﬁ  rming the ﬁ  ndings of a 
previous study [54]. Such a result may suggest that the 8.1 
haplotype not only inﬂ  uences susceptibility for IBM but 
also may aﬀ  ect clinical disease expression.
Similarities have previously been noted in accumulated 
proteins from sporadic IBM muscle biopsies and brain 
tissue plaques from Alzheimer’s disease cases, including 
amyloid-β precursor protein, amyloid-β, and apolipo-
protein E (apoE) [55]. Th  e APOE gene was previously 
investigated in sporadic IBM [52]. A gene expression 
mRNA proﬁ  ling study has demonstrated the increased 
expression of amyloid and apoE in IBM, but signiﬁ  cantly 
elevated levels of the same genes were also found in the 
biopsies of PM and DM cases (in which the expression of 
these proteins is not typically found). Th  ese ﬁ  ndings 
suggest that the observed accumulation of these proteins 
in IBM may be due to post-transcriptional events down-
stream of mRNA expression [56].
Dissecting genetic associations to identify the 
functional variants
As indicated above, it is becoming increasingly clear from 
published research that multiple genes and genetic 
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involved in susceptibility to autoimmune disorders. 
Identi ﬁ  cation of the precise role of speciﬁ  c HLA alleles is 
com  plicated by the presence of extensive linkage dis-
equili  brium across common autoimmune risk haplo-
types; analyses conditional on known genetic risk 
variants have been carried out in an attempt to alleviate 
this problem and to identify independent signals. 
Further  more, the majority of research to date has been 
published on Caucasian populations, and it is not yet 
clear how much variability in disease susceptibility there 
is between diﬀ  erent ethnic groups. Further multiethnic 
comparisons may help to identify the functional genetic 
variants and to interpret diﬀ  erences in clinical presen-
tation and disease severity between diﬀ  erent populations.
Conclusions
Th   is review illustrates the progress that has been made in 
IIM immunogenetic research over the past decade. A 
substantial part of the genetic risk for developing adult- 
and juvenile-onset IIM lies within the MHC, but multiple 
genetic regions outside of the MHC are increasingly 
being identiﬁ  ed as conferring disease susceptibility risk. 
Th  ere is still the challenge of studying a serologically 
heterogeneous disorder that is rarer by orders of 
magnitude than the likes of rheumatoid arthritis. Never-
theless, ﬁ  ndings increasingly appear to demonstrate the 
strong relationship between HLA genotype and IIM 
serological/clinical phenotype. Further and larger 
collabora  tive studies will help to discern whether an 
individual’s genotype will assist the attending physician 
in the assessment of disease severity and outcome. 
Th   rough MYOGEN, a fully international Myositis 
Genetics Consortium, a genome-wide association scan is 
already being undertaken and analyzed. It is hoped that 
the results will repeat the successes already demonstrated 
in other autoimmune diseases and that post-genomic 
work in IIM will result in the identiﬁ   cation of novel 
disease susceptibility variants. Exciting times beckon in 
the diﬃ   cult ﬁ  eld of IIM immunogenetics!
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